Smart drug matching during kidney transplant could boost success
NCT ID NCT07633600
First seen Jun 11, 2026 · Last updated Jun 24, 2026 · Updated 3 times
Summary
This study tests whether giving specific blood pressure drugs based on a patient's circulation type during kidney transplant surgery improves how the body responds to fluids. Researchers will monitor 255 adults and assign drugs like vasopressin or norepinephrine based on real-time heart and blood vessel measurements. The goal is to see if this personalized approach leads to better blood pressure control and fluid management during the operation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vasopressin, Norepinephrine, Calcium Chloride, Dopamine
What this could lead to
If successful, this could lead to better blood pressure and fluid management during kidney transplant surgery, potentially improving outcomes.
What could go wrong
This is a single-center Phase 4 trial that has not yet started recruiting. The approach is experimental and may not improve patient outcomes or be generalizable to other centers.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.